Imagine discovering that a silent intruder has been wreaking havoc on your brain for years, long before you even noticed anything was wrong. That's the chilling reality of multiple sclerosis (MS), a disease that stealthily damages the brain far earlier than symptoms appear. But here's where it gets even more startling: recent research reveals that this damage starts much sooner than anyone previously thought. And this is the part most people miss—it’s not just about when the symptoms show up; it’s about what’s happening invisibly, years in advance.
Scientists at UC San Francisco have made a groundbreaking discovery by analyzing thousands of proteins in the blood, painting the clearest picture yet of how MS attacks the myelin sheath—the protective layer around nerve fibers. Their findings, published in Nature Medicine (https://www.nature.com/articles/s41591-025-04014-w), show that the immune system begins its assault on the brain far earlier than previously believed. This isn’t just a scientific breakthrough; it’s a potential gamechanger for diagnosing and even preventing MS.
Here’s how it works: The study measured the debris left behind by these immune attacks in the blood, along with the signals that trigger the immune system to strike. For the first time, researchers have mapped the sequence of events that lead to MS. It starts with the immune system targeting the fatty myelin sheath, and about a year later, the breakdown of nerve fibers themselves becomes visible. But here’s the controversial part: Could this mean that MS is preventable if caught early enough? And if so, why aren’t we already screening for it?
One protein, in particular, stood out in the early stages of the disease: IL-3. This protein plays a critical role in recruiting immune cells to the brain and spinal cord, where they attack nerve cells. The catch? Patients don’t feel any symptoms during this phase, even as their central nervous system suffers significant damage. This raises a thought-provoking question: If we can detect IL-3 early, could we intervene before irreversible harm occurs?
The researchers analyzed over 5,000 proteins in blood samples from 134 people with MS, both before and after their diagnosis. These samples came from the U.S. Department of Defense Serum Repository, a treasure trove of data from military service members. Seven years before diagnosis, they observed a spike in a protein called MOG (myelin oligodendrocyte glycoprotein), which signals damage to the myelin sheath. A year later, another protein, neurofilament light chain, spiked, indicating damage to the nerve fibers themselves. During this period, IL-3 and related proteins orchestrating the immune attack appeared in the blood.
The team identified about 50 proteins that could predict future MS development and has filed a patent application for a diagnostic blood test using the top 21 of them. But here’s where it gets controversial: If such a test becomes available, who should get screened? And what ethical considerations arise if we can predict a disease years before symptoms appear?
Ahmed Abdelhak, MD, assistant professor of Neurology at UCSF and lead author of the study, believes this work could revolutionize how we approach MS. “It could be a gamechanger for how we understand and manage this disease,” he said. Ari Green, MD, senior author and chief of the Division of Neuroimmunology and Glial Biology at UCSF, added, “We now know that MS starts way earlier than the clinical onset, creating the real possibility that we could someday prevent MS—or at least use our understanding to protect people from further injury.”
This research not only offers hope for prevention but also deepens our understanding of what triggers MS symptoms. But here’s the question we can’t ignore: With this knowledge, are we doing enough to act on it? What do you think? Should early screening for MS become a standard practice, or are there too many unknowns? Let’s start the conversation in the comments.
For more details, check out the full study: Abdelhak, A. et al. Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis, Nature Medicine (2025). DOI: 10.1038/s41591-025-04014-w (https://dx.doi.org/10.1038/s41591-025-04014-w).
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
